The FDA’s medical device advisory committee is scheduled to vote on a recommendation regarding Galleri, a multi-cancer blood test developed by Grail that the company claims can identify up to 50 different cancer forms. The panel will hear presentations from Grail representatives, FDA officials, and members of the public before making its recommendation. While the FDA typically follows advisory committee guidance, final approval decisions remain the agency’s responsibility. Approval could lead to insurance coverage for the test, which carries a cost of $949.
Galleri represents the first multi-cancer blood test to undergo comprehensive FDA safety and accuracy review, though other cancer-detection blood tests already exist on the market. The company positions the test as complementary to existing screening methods such as colonoscopies and mammograms, rather than as a replacement. Congress previously authorized Medicare coverage for multi-cancer detection tests approved by the FDA, significantly increasing financial incentives for companies pursuing regulatory clearance. The FDA granted expedited review status to Galleri based on its potential clinical impact.
The advisory committee will examine data from two major clinical trials. One study involved more than 140,000 patients in the UK’s National Health System, while the other included over 35,000 North American patients, all older than 50. The studies’ results have generated some discussion within the medical community. While Galleri did not achieve its primary endpoint of reducing overall mortality or decreasing combined Stage III and IV cancer diagnoses, subsequent analysis of the NHS trial data indicated that Stage IV cancer diagnoses alone declined during the three-year study period, suggesting the test may shift cancer detection to earlier stages.
Experts acknowledge the studies did not fully demonstrate the test’s mortality benefits, but some attribute this partly to ambitious study goals and short timeframes. Long-term mortality reductions are typically measured over extended periods, and initial testing years often reveal previously existing late-stage cancers in the population. The underlying question for regulators, doctors, and patients centers on whether the test possesses sufficient accuracy and reliability to detect cancers early enough to meaningfully reduce cancer deaths. Some clinical observers suggest longer-term studies will be necessary to confirm whether regular testing can sustainably shift diagnoses toward earlier stages and improve patient outcomes.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI